Pasithea Therapeutics Corp. (KTTA)

Pasithea Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-13.49	-13.9	-15.51	-11.73	-2.17
Depreciation & Amortization	0.67	0.65	0.65	0.01	0
Stock-Based Compensation	0.39	0.77	0.59	0.84	0.47
Other Adjustments	-0.01	0.08	-0.12	-1.85	-1.58
Changes in Accounts Payable	0.7	-1.43	1.07	0.75	0.44
Changes in Other Operating Activities	-0.45	-0.09	0.5	0.1	-0.33
Operating Cash Flow	-12.26	-13.92	-12.81	-11.89	-3.17
Capital Expenditures	-	-	-0.03	-0.11	-0.02
Sale of Property, Plant & Equipment	-	-	0.11	-	-
Payments for Business Acquisitions	-	-	-	-2.19	-
Investing Cash Flow	-	-	0.08	-2.3	-0.02
Long-Term Debt Issued	-	-	0.39	-	-
Long-Term Debt Repaid	-	-	-0.39	-	-
Issuance of Common Stock	4.76	5	-	-	57.24
Repurchase of Common Stock	-	-	-3.73	-3.21	-
Net Common Stock Issued (Repurchased)	4.76	5	-3.73	-3.21	57.24
Other Financing Activities	-0.43	-0.48	-	-	-1.31
Financing Cash Flow	7.07	4.52	-3.73	-3.21	55.93
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.05	-0	-0	0.01	-0.01
Net Cash Flow	-3.22	-9.41	-16.76	-19.81	52.72
Free Cash Flow	-12.26	-13.92	-12.85	-12	-3.2
FCF Margin	-	-	-	-	-21216.05%
Free Cash Flow Per Share	-2.96	-12.70	-10.47	-9.51	-6.14
Levered Free Cash Flow	-12.58	-14.77	-13.77	-13.19	-2.08
Unlevered Free Cash Flow	-6.03	-15.12	-13.79	-11.85	-4.42

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q